News Release
Mallinckrodt to Present at J.P. Morgan Healthcare Conference
DUBLIN--(BUSINESS WIRE)--Jan. 2, 2014--
Mallinckrodt
plc (NYSE: MNK), a global specialty pharmaceutical and global medical
imaging company, will present at the 32nd Annual J.P. Morgan
Healthcare Conference in San Francisco on January 15, 2014. Mark
Trudeau, President and Chief Executive Officer of Mallinckrodt, will
represent the company in a session scheduled to begin at 2:30pm PST
(5:30pm EST).
Individuals who are unable to attend the meeting in person will be able
to view a live video and webcast at: http://mallinckrodt.com/investor_relations.
A replay will be available on the website following the conclusion of
the meeting.
ABOUT MALLINCKRODT:
Mallinckrodt is a global specialty pharmaceutical and medical imaging
business that develops, manufactures, markets and distributes specialty
pharmaceutical products and medical imaging agents. The company’s
Specialty Pharmaceuticals segment includes branded and generic drugs and
active pharmaceutical ingredients, and the Global Medical Imaging
segment includes contrast media and nuclear imaging agents. Mallinckrodt
has approximately 5,500 employees worldwide and a commercial presence in
roughly 70 countries. The company’s fiscal 2013 revenue totaled $2.2
billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Source: Mallinckrodt
Mallinckrodt
John Moten, 314-654-6650
Vice President, Investor
Relations
john.moten@mallinckrodt.com
or
Lynn
Phillips, 314-654-3263
Manager, Media Relations
lynn.phillips@mallinckrodt.com
